TLR4 and stroke disorder: by investigating effects of xyloketal in an adult mice stroke model, observing that pre- and post-treatment treatment reduced both brain infarct volume and the generation of ROS and pro-inflammatory cytokines by suppression of ROS/TLR4/NF-κB inflammatory signaling pathway, thus providing evidence for “potential application of xyloketal B in stroke therapy” [246].